001     124312
005     20240228145506.0
024 7 _ |a 10.1016/j.omtn.2016.12.001
|2 doi
024 7 _ |a pmid:28325279
|2 pmid
024 7 _ |a pmc:PMC5363413
|2 pmc
037 _ _ |a DKFZ-2017-01208
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Afzal, Saira
|0 P:(DE-He78)919864a40f3154bace897117e0e2387e
|b 0
|e First author
|u dkfz
245 _ _ |a GENE-IS: Time-Efficient and Accurate Analysis of Viral Integration Events in Large-Scale Gene Therapy Data.
260 _ _ |a New York, NY
|c 2017
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1509018058_1757
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Integration site profiling and clonality analysis of viral vector distribution in gene therapy is a key factor to monitor the fate of gene-corrected cells, assess the risk of malignant transformation, and establish vector biosafety. We developed the Genome Integration Site Analysis Pipeline (GENE-IS) for highly time-efficient and accurate detection of next-generation sequencing (NGS)-based viral vector integration sites (ISs) in gene therapy data. It is the first available tool with dual analysis mode that allows IS analysis both in data generated by PCR-based methods, such as linear amplification method PCR (LAM-PCR), and by rapidly evolving targeted sequencing (e.g., Agilent SureSelect) technologies. GENE-IS makes use of trimming strategies, customized reference genome, and soft-clipped information with sequential filtering steps to provide annotated IS with clonality information. It is a scalable, robust, precise, and reliable tool for large-scale pre-clinical and clinical data analysis that provides users complete flexibility and control over analysis with a broad range of configurable parameters. GENE-IS is available at https://github.com/G100DKFZ/gene-is.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Wilkening, Stefan
|0 P:(DE-He78)928f784868a4b5ff301367ecda92f152
|b 1
700 1 _ |a von Kalle, Christof
|0 P:(DE-He78)5bacb661d5d7c0220d8f996d980ad8de
|b 2
700 1 _ |a Schmidt, Manfred
|0 P:(DE-He78)b91bec47a4148ba68a58ab292d5860f2
|b 3
700 1 _ |a Fronza, Raffaele
|0 P:(DE-He78)c2585457f370249465a2080111937cf5
|b 4
|e Last author
773 _ _ |a 10.1016/j.omtn.2016.12.001
|g Vol. 6, p. 133 - 139
|0 PERI:(DE-600)2662631-7
|p 133 - 139
|t Molecular Therapy / Nucleic Acids
|v 6
|y 2017
|x 2162-2531
909 C O |o oai:inrepo02.dkfz.de:124312
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)919864a40f3154bace897117e0e2387e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)928f784868a4b5ff301367ecda92f152
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)5bacb661d5d7c0220d8f996d980ad8de
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)b91bec47a4148ba68a58ab292d5860f2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)c2585457f370249465a2080111937cf5
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|2 G:(DE-HGF)POF3-300
|v Translational cancer research
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2017
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOL THER-NUCL ACIDS : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)
|0 LIC:(DE-HGF)CCBYNCNDNV
|2 V:(DE-HGF)
|b DOAJ
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOL THER-NUCL ACIDS : 2015
920 1 _ |0 I:(DE-He78)G010-20160331
|k G010
|l Geschäftsstelle
|x 0
920 1 _ |0 I:(DE-He78)G100-20160331
|k G100
|l Translationale Onkologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G010-20160331
980 _ _ |a I:(DE-He78)G100-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21